PHILADELPHIA, Nov. 1, 2021 /PRNewswire/ -- ASMS 2021
–Thermo Fisher Scientific Inc. (NYSE: TMO), the world
leader in serving science, is empowering scientists to drive
groundbreaking discoveries with the introduction of new-generation
mass spectrometry instruments, workflows and software. The company
will showcase new additions to its industry-leading offering during
the 69th American Society for Mass Spectrometry (ASMS)
Conference on Mass Spectrometry and Allied Topics, being held
October 31-November 4, in the
Pennsylvania Convention Center,
Philadelphia, Pennsylvania.
"The life science industry has stepped forward in an
unprecedented fashion over the last 18 months, with academia and
biopharma making key contributions to respond to the pandemic,"
said Dan Shine, senior vice
president and president, analytical instruments, Thermo Fisher
Scientific. "We're honored to have played an essential role in this
effort. The new instruments, software and workflows that
we're unveiling today will further support innovation across
proteomics, biopharmaceutical characterization and data acquisition
while also ensuring that scientists can continue their critical
ongoing research."
Mass spectrometer streamlines biopharmaceutical development
and quality control (QC)
The Thermo Scientific Orbitrap Exploris MX mass detector allows
biopharmaceutical laboratories to easily implement multi-attribute
method (MAM), and perform intact analysis of monoclonal
antibodies, oligonucleotide mass determination and peptide mapping.
To simplify the transition of biotherapeutics from development to
manufacturing, the new system enables QC customers to use the same
method established earlier in a molecule's journey to
commercialization, accelerating the biopharmaceutical pipeline. For
further efficiency gains, laboratories can benefit from
reduced downtime and maintenance, as well as seamless method
transfers. The new system offers superior data quality and,
therefore, high-confidence results, even for users with limited
mass spectrometric experience.
Updated MAM workflow bridges the gap between development and
manufacturing
The Thermo Scientific MAM 2.0 workflow streamlines
biopharmaceutical characterization, process monitoring and release
testing by replacing multiple traditional assays with one
comprehensive analysis, delivering insights on multiple critical
product quality attributes. MAM 2.0 includes the training, on-going
support and partnership required for laboratories to enhance their
analytical workflows across R&D, manufacturing and QC
environments. To remove the bottlenecks often seen by organizations
moving therapeutics from development to manufacturing, the new
workflow enables the use of the same platform throughout the entire
process, ultimately creating an end-to-end solution allowing
for the seamless transfer of data and knowledge across teams and
departments.
Advanced software leverages new technology to enhance data
acquisition and analysis
For proteomic researchers, the combination of Thermo Scientific
Proteome Discoverer 3.0 software with CHIMERYS by MSAID will
greatly increase their ability to identify peptides and proteins,
allowing for a wider and deeper understanding of biological
systems. By leveraging artificial intelligence (AI) to reimagine
the analysis of tandem mass spectra, peptide coverage and
quantitation capabilities are increased, unlocking exciting new
possibilities for proteomics researchers.
To provide scientists performing small molecule analysis in
metabolomics, environmental, food safety, clinical and forensics
laboratories with faster and more sensitive compound detection, the
Thermo Scientific Compound Discoverer 3.3 software offers an
enhanced peak detection algorithm and improved peak quality
rating.
The Thermo Scientific BioPharma Finder 5.0 software creates new
capabilities for biotherapeutic workflows by increasing
analytical throughput and confidence through built for purpose data
processing, curation and customizable reporting. The secure
environment enables global collaboration and can be used across
multiple application workflows, such as peptide mapping analysis,
oligonucleotide analysis, intact mass analysis and top down
analysis.
Finally, the Thermo Scientific LipidSearch 5.0 software now
supports direct infusion workflows and features an extensive
database of 1.5 million lipids, enabling real time monitoring in
addition to more accurate lipid quantitation.
For more details on Thermo
Fisher's activities at ASMS, please visit
www.thermofisher.com/ASMS.
About Thermo Fisher Scientific
Thermo Fisher
Scientific Inc. is the world leader in serving science, with annual
revenue of approximately $35 billion.
Our Mission is to enable our customers to make the world healthier,
cleaner and safer. Whether our customers are accelerating life
sciences research, solving complex analytical challenges, improving
patient diagnostics and therapies or increasing productivity in
their laboratories, we are here to support them. Our global team of
more than 90,000 colleagues delivers an unrivaled combination of
innovative technologies, purchasing convenience and pharmaceutical
services through our industry-leading brands, including Thermo
Scientific, Applied Biosystems, Invitrogen, Fisher Scientific,
Unity Lab Services and Patheon. For more information, please
visit www.thermofisher.com.
Media Contact
Information:
Charlotte
McCormack
|
Investor Contact
Information:
Rafael
Tejada
|
Phone:
781-622-1202
|
Phone:
781-622-1356
|
E-mail:
charlotte.mccormack@thermofisher.com
|
E-mail:
rafael.tejada@thermofisher.com
|
View original
content:https://www.prnewswire.com/news-releases/thermo-fisher-scientific-launches-new-mass-spectrometry-and-chromatography-solutions-at-asms-2021-301412868.html
SOURCE Thermo Fisher Scientific